Differential Expression of Programmed Death-1 (PD-1) in Sézary Syndrome and Mycosis Fungoides
Overview
Affiliations
OBJECTIVE To determine if there are differences in the expression of programmed death-1 (PD-1) between SS and MF, and in particular erythrodermic MF (E-MF). PD-1 is a marker of follicular helper T (TFH) cells and is expressed by the neoplastic T cells of some types of malignant T-cell lymphoma, including mycosis fungoides (MF) and Sézary syndrome (SS). Reported results of PD-1 staining in MF and SS are, however, conflicting. DESIGN Formalin-fixed, paraffin-embedded skin biopsy specimens were stained for PD-1. In addition, PD-1+ cases were stained with antibodies against BCL6, CXCL13, and CD10 to find possible relationship with TFH cells. SETTING Tertiary referral center for cutaneous lymphomas. PATIENTS Twenty-seven patients with SS and 60 patients with MF, including 8 patients with E-MF. RESULTS In patients with SS, expression of PD-1 by more than 50% of the neoplastic T cells was observed in 24 of 27 cases (89%). In contrast, PD-1 expression by more than 50% of neoplastic T cells was found in only 8 of 60 patients with MF (13%), including only 1 of 8 patients with E-MF (12%). In PD-1+ cases, serial skin sections showed that CXCL13 and BCL6 generally stained 25% to 50% of the PD-1+ cells, while expression of CD10 was uncommon. CONCLUSION The results of the present study show differential expression of PD-1 between SS and MF/E-MF, which provides further support for the view that SS and MF are distinct entities.
[Differential diagnosis of epidermotropic neoplasia].
Moritz R, Ghoreschi F Dermatologie (Heidelb). 2025; 76(3):140-151.
PMID: 39961813 DOI: 10.1007/s00105-025-05470-8.
Advances in Novel Systemic Therapies for the Management of Cutaneous T Cell Lymphoma (CTCL).
Case K, Allen P Curr Hematol Malig Rep. 2025; 20(1):5.
PMID: 39800801 DOI: 10.1007/s11899-024-00746-7.
Targeting TAG-72 in cutaneous T cell lymphoma.
Evtimov V, Hammett M, Pupovac A, Nguyen N, Shu R, Van Der Weyden C Heliyon. 2024; 10(17):e36298.
PMID: 39263154 PMC: 11386021. DOI: 10.1016/j.heliyon.2024.e36298.
Dar N, Roberts N, Gru A, Obiorah I, Zheng J, Kostakoglu Shields L JAAD Case Rep. 2024; 48:18-22.
PMID: 38741658 PMC: 11090057. DOI: 10.1016/j.jdcr.2024.03.016.
Elmasry M, Mosaad R, Azzam O, Rashed L, Fahim A Arch Dermatol Res. 2024; 316(3):97.
PMID: 38430309 PMC: 10908618. DOI: 10.1007/s00403-024-02838-z.